Personalized Medicine

Evolving Immuno-Oncology Strategies in Renal-Cell Carcinoma

Wayne Kuznar

June 2019, Vol 10, No 3 - Immunotherapy

San Francisco, CA—The era of immunotherapy has opened new perspectives in renal-cell carcinoma (RCC), which is one of the tumors most highly infiltrated with CD T-cells and PD-1 expression, partially accounting for its sensitivity to immunotherapy. Other mechanisms to explain its sensitivity include myeloid infiltration, metabolic alterations, loss-of-function mutations, and human endogenous retroviruses. [ Read More ]

Can Immunotherapy Work in Ovarian Cancer?

Wayne Kuznar

June 2019, Vol 10, No 3 - Immunotherapy, Ovarian Cancer

San Francisco, CA—Patients with ovarian cancer can respond to immunotherapy, but rationally designed synergistic combinations will be necessary to enhance upfront efficacy and to sustain durability, said Daniel J. Powell Jr, PhD, Scientific Director of Immunotherapy, Division of Gynecologic Oncology, Center for Cellular Immunotherapy, University of Pennsylvania, Philadelphia, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. [ Read More ]

First Positive Showing for Mesothelin-Directed CAR T-Cell Therapy in Solid Tumors

Phoebe Starr

June 2019, Vol 10, No 3 - Immunotherapy

Atlanta, GA—Chimeric antigen receptor (CAR) T-cell therapy has had dramatic results in hematologic malignancies, but so far, getting CAR T-cells to work in solid tumors has proved elusive. That may be about to change if promising results from a phase 1 clinical trial are confirmed by further studies. The results of this pivotal study were presented at the 2019 American Association for Cancer Research (AACR) annual meeting. [ Read More ]

Infigratinib a Novel, Potent Selective TKI Targeting FGFR Fusions in Different Tumor Types

Phoebe Starr

June 2019, Vol 10, No 3 - Emerging Therapies

Atlanta, GA—Preclinical and clinical data support the potential for the investigational novel tyrosine kinase inhibitor (TKI) infigratinib for the treatment of different FGFR-driven tumor types, according to Sameek Roychowdhury, MD, PhD, Associate Professor, Medical Oncology, the Ohio State University, Columbus, who presented a poster with the preclinical results at the 2019 American Association for Cancer Research (AACR) meeting. [ Read More ]

Osimertinib plus Savolitinib Promising for Advanced Non–Small-Cell Lung Cancer and MET-Driven Resistance

Phoebe Starr

June 2019, Vol 10, No 3 - Lung Cancer

Atlanta, GA—The combination of the investigational MET inhibitor savolitinib plus the EGFR inhibitor osimertinib (Tagrisso) achieved encouraging responses in patients with MET-amplified, EGFR-positive non–small-cell lung cancer (NSCLC) and acquired, MET-driven resistance to previous therapies, with an acceptable side-effect profile. These findings represent interim results of 2 expansion cohorts of a phase 1b clinical trial presented at the 2019 American Association for Cancer Research meeting. [ Read More ]

Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation

Phoebe Starr

June 2019, Vol 10, No 3 - Leukemia

Atlanta, GA—Treatment with gilteritinib (Xospata) significantly improved overall survival (OS) with less toxicity compared with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and FLT3 mutation, according to the final results of ADMIRAL, a phase 3 clinical trial presented at the 2019 American Association for Cancer Research meeting. [ Read More ]

Paradigm Shift: Ibrutinib plus Rituximab Front-Line Therapy for Patients Age 70 or Younger with CLL

Phoebe Starr

June 2019, Vol 10, No 3 - Leukemia

San Diego, CA—The combination of the targeted therapy ibrutinib (Imbruvica), a protein kinase inhibitor, and the monoclonal antibody rituximab (Rituxan) extends disease-free survival by 65% and overall survival (OS) by 83% compared with standard-of-care chemotherapy with the fludarabine plus cyclophosphamide and rituximab (FCR) regimen as first-line therapy in patients with chronic lymphocytic leukemia (CLL) under age 70, according to results of the phase 3 ECOG-ACRIN 1912 trial presented at a late-breaking abstract session at ASH 2018. [ Read More ]

CAR T-Cell Therapy Augments Response to Ibrutinib in Chronic Lymphocytic Leukemia

Phoebe Starr

June 2019, Vol 10, No 3 - Leukemia

San Diego, CA—Results with chimeric antigen receptor (CAR) T-cell therapy have been less robust in chronic lymphocytic leukemia (CLL) compared with B-cell acute lymphocytic leukemia and diffuse large B-cell lymphoma. Preliminary studies presented at ASH 2018 suggested that a strategy of using CAR T-cell therapy to augment the response to ibrutinib (Imbruvica) holds promise in patients with CLL. [ Read More ]

Updated NCCN Guideline Strongly Recommends Germline Testing for All Patients with Pancreatic Cancer

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference, Pancreatic Cancer

Orlando, FL—Germline testing should now be considered for any patient with pancreatic cancer, and molecular analysis of tumors should be considered in patients with metastatic disease, according to the updated National Comprehensive Cancer Network (NCCN) guideline for pancreatic cancer presented at the 2019 NCCN Conference. [ Read More ]